Drug Profile
Cilengitide companion diagnostic - MDxHealth
Alternative Names: PredictMDx™ for GlioblastomaLatest Information Update: 31 Aug 2015
Price :
$50
*
At a glance
- Originator MDxHealth
- Developer MDxHealth; Merck KGaA
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 09 Jun 2011 Phase-III clinical trials in Glioblastoma in European Union (Ex vivo)
- 09 Jun 2011 Phase-III clinical trials in Glioblastoma in USA (Ex vivo)